Home › Therapeutic areas › Immunology
Immunology (57 companies · 22 conditions)
Conditions
Systemic Lupus Erythematosus 15 Rheumatoid Arthritis 13 Systemic Sclerosis 12 Rare Chronic Urticaria 8 Idiopathic Inflammatory Myopathies 8 Rare Ulcerative Colitis 8 Crohn's Disease 6 Sjögren's Syndrome 6 Dermatomyositis 3 Rare Graves' Disease 3 Hereditary Angioedema 3 Rare Psoriatic Arthritis 3 ANCA-Associated Vasculitis 2 Rare Food Allergy 2 Graft-versus-Host Disease 2 Rare IgG4-Related Disease 2 Rare Axial Spondyloarthritis 1 Cow's Milk Allergy 1 Leukocyte Adhesion Deficiency-I 1 Rare Peanut Allergy 1 Primary Humoral Immunodeficiency 1 Rare Transplant Rejection 1 Rare
Companies
| Ticker | Company | Therapeutic areas | In Immunology | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ABVX | Abivax | Immunology | 2 | Phase 3 | $7.19B | 2 |
| ACET | Adicet Bio | ImmunologyNeurology+2 Rare | 5 | Phase 1 | $26.0M | 8 |
| ADMA | Adma Biologics | ImmunologyInfectious Disease Rare | 2 | Approved | $3.02B | 4 |
| AGMB | Agomab Therapeutics | ImmunologyRespiratory Rare | 1 | Phase 2 | $292M | 4 |
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | 3 | Phase 2 | $256M | 10 |
| ALMS | Alumis | DermatologyImmunology+1 | 3 | Phase 3 | $628M | 5 |
| ANAB | AnaptysBio | DermatologyGI/Hepatology+2 Rare | 1 | Approved | $1.36B | 9 |
| RCUS | Arcus Biosciences | DermatologyImmunology+1 | 1 | Phase 3 | $2.36B | 8 |
| AUTL | Autolus Therapeutics | HematologyImmunology+3 Rare | 1 | Approved | $290M | 12 |
| BCRX | Biocryst Pharmaceuticals | DermatologyImmunology+1 Rare | 2 | Approved | $1.93B | 4 |
| CABA | Cabaletta Bio | DermatologyImmunology+2 Rare | 5 | Phase 2 | $220M | 8 |
| RNAC | Cartesian Therapeutics | ImmunologyNeurology+1 Rare | 2 | Phase 3 | $187M | 4 |
| CLDX | Celldex Therapeutics | DermatologyImmunology+1 | 4 | Phase 3 | $2.20B | 6 |
| IPSC | Century Therapeutics | ImmunologyMetabolic+1 Rare | 6 | Phase 1 | $249M | 9 |
| CMMB | Chemomab Therapeutics | GI/HepatologyImmunology+1 Rare | 2 | Phase 2 | $13.2M | 4 |
| CLYM | Climb Bio | HematologyImmunology+1 Rare | 2 | Phase 2 | $574M | 8 |
| CUE | Cue Biopharma | ImmunologyOncology | 2 | Phase 2 | $23.7M | 6 |
| CGEM | Cullinan Therapeutics | HematologyImmunology+2 Rare | 4 | NDA Submitted | $602M | 10 |
| DBVT | DBV Technologies | Immunology | 2 | NDA Submitted | $3.14B | 2 |
| ELDN | Eledon Pharmaceuticals | ImmunologyMetabolic+1 Rare | 1 | Phase 2 | $167M | 3 |
| ENTA | Enanta Pharmaceuticals | DermatologyImmunology+2 | 1 | Approved | $253M | 8 |
| EVMN | Evommune | DermatologyImmunology+1 | 3 | Phase 2 | $290M | 6 |
| FATE | Fate Therapeutics | ImmunologyOncology+1 Rare | 4 | Phase 2 | $124M | 10 |
| IMVT | Immunovant | ImmunologyNeurology Rare | 2 | Phase 3 | $6.87B | 4 |
| INAB | IN8bio | ImmunologyOncology | 1 | Phase 1 | $8.9M | 4 |
| INSM | Insmed | CardiovascularImmunology+3 Rare | 1 | Approved | $26.7B | 15 |
| NTLA | Intellia Therapeutics | CardiovascularImmunology Rare | 1 | NDA Submitted | $1.37B | 3 |
| IONS | Ionis Pharmaceuticals | CardiovascularHematology+5 Rare | 1 | Approved | $4.49B | 29 |
| JBIO | Jade Biosciences | ImmunologyRenal Rare | 2 | Phase 2 | $1.07B | 4 |
| KYMR | Kymera Therapeutics | DermatologyImmunology+1 Rare | 1 | Phase 2 | $10.4B | 5 |
| KYTX | Kyverna Therapeutics | ImmunologyNeurology+1 Rare | 1 | NDA Submitted | $297M | 6 |
| LQDA | Liquidia | CardiovascularImmunology+1 Rare | 1 | Approved | $5.11B | 9 |
| MGTX | MeiraGTx | ImmunologyMetabolic+2 Rare | 1 | Phase 3 | $827M | 16 |
| MESO | Mesoblast | CardiovascularGI/Hepatology+2 Rare | 0 | Approved | $1.54B | 5 |
| INKT | MiNK Therapeutics | ImmunologyOncology+1 Rare | 1 | Phase 2 | $47.7M | 8 |
| GLUE | Monte Rosa Therapeutics | CardiovascularDermatology+3 Rare | 1 | Phase 2 | $775M | 7 |
| MLTX | MoonLake Immunotherapeutics | DermatologyImmunology Rare | 2 | NDA Submitted | $957M | 4 |
| NKTR | Nektar Therapeutics | DermatologyImmunology+2 | 1 | Phase 3 | $1.23B | 11 |
| NKTX | Nkarta | ImmunologyNeurology+1 Rare | 5 | Phase 1 | $89.6M | 8 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 1 | Phase 3 | $1.56B | 13 |
| ORKA | Oruka Therapeutics | DermatologyImmunology Rare | 1 | Phase 2 | $6.53B | 7 |
| PTN | Palatin Technologies | ImmunologyMetabolic+1 | 1 | Phase 3 | $9.5M | 5 |
| PALI | Palisade Bio | Immunology | 2 | Phase 2 | $181M | 3 |
| PCSA | Processa Pharmaceuticals | GI/HepatologyImmunology+2 Rare | 2 | Phase 2 | $4.8M | 7 |
| PTGX | Protagonist Therapeutics | DermatologyHematology+2 Rare | 3 | Approved | $8.14B | 12 |
| QNRX | Quoin Pharmaceuticals | DermatologyImmunology Rare | 1 | Phase 2 | $236M | 4 |
| RCKT | Rocket Pharmaceuticals | CardiovascularImmunology Rare | 1 | Approved | $236M | 4 |
| SEPN | Septerna | ImmunologyMetabolic+1 Rare | 3 | Phase 1 | $1.90B | 5 |
| SYRE | Spyre Therapeutics | DermatologyImmunology Rare | 9 | Phase 2 | $8.91B | 10 |
| SNDX | Syndax Pharmaceuticals | ImmunologyOncology Rare | 1 | Approved | $822M | 7 |
| TLSA | Tiziana Life Sciences | ImmunologyNeurology Rare | 1 | Phase 2 | $83.2M | 5 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 1 | Approved | $230M | 27 |
| VRDN | Viridian Therapeutics | ImmunologyOphthalmology | 2 | Approved | $3.41B | 7 |
| VOR | Vor Biopharma | ImmunologyNeurology Rare | 1 | Phase 3 | $1.12B | 2 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 10 | Approved | $2.59B | 28 |
| ZBIO | Zenas BioPharma | DermatologyImmunology+2 Rare | 3 | NDA Submitted | $1.88B | 11 |
| ZURA | Zura Bio | DermatologyImmunology Rare | 1 | Phase 2 | $99.7M | 4 |
No companies match.